Literature DB >> 19585587

Focusing effects of L-dopa in Parkinson's disease.

Bernard Ng1, Samantha Palmer, Rafeef Abugharbieh, Martin J McKeown.   

Abstract

Previous fMRI motor studies in Parkinson's disease (PD) have suggested that L-dopa may "normalize" areas of hypo- and hyperactivity. However, results from these studies, which were largely based on analyzing BOLD signal amplitude, have been conflicting. Examining only amplitude changes at distinct loci may thus be inadequate in fully capturing the activation changes induced by L-dopa. In this article, we extended prior analyses on the effects of L-dopa by investigating both amplitude and spatial changes of brain activation before and after L-dopa. Ten subjects with PD, both on and off medication, and ten healthy, age-matched controls performed a visuo-motor tracking task in which they sinusoidally squeezed a bulb at 0.25, 0.5, and 0.75 Hz. This task was contrasted with static squeezing to generate fMRI activation maps. To investigate the effects of L-dopa, we examined the amplitude and spatial variance of the BOLD response within anatomically-defined regions of interest (ROIs). L-dopa had significant main effects on the amplitude of BOLD signal in bilateral primary motor cortex and left SMA. In contrast, L-dopa-mediated spatial changes were apparent in bilateral cerebellar hemispheres, M1, SMA, and right prefrontal cortex. Moreover, L-dopa appeared to normalize the spatial distribution of ROI activation in PD to that of the controls. Specifically, L-dopa had a "focusing" effect on activity-an effect more pronounced than the typically-measured fMRI amplitude changes. This observation is consistent with modeling studies, which demonstrated that dopamine increases the signal-to-noise ratio at the neuronal level with a resultant focusing of representations at the macroscopic level. 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19585587      PMCID: PMC6870674          DOI: 10.1002/hbm.20847

Source DB:  PubMed          Journal:  Hum Brain Mapp        ISSN: 1065-9471            Impact factor:   5.038


  30 in total

1.  Event-related functional magnetic resonance imaging in Parkinson's disease before and after levodopa.

Authors:  B Haslinger; P Erhard; N Kämpfe; H Boecker; E Rummeny; M Schwaiger; B Conrad; A O Ceballos-Baumann
Journal:  Brain       Date:  2001-03       Impact factor: 13.501

2.  Metabolic correlates of levodopa response in Parkinson's disease.

Authors:  A Feigin; M Fukuda; V Dhawan; S Przedborski; V Jackson-Lewis; M J Mentis; J R Moeller; D Eidelberg
Journal:  Neurology       Date:  2001-12-11       Impact factor: 9.910

3.  Corticostriatal functional interactions in Parkinson's disease: a rTMS/[11C]raclopride PET study.

Authors:  Antonio P Strafella; Ji Hyun Ko; Joshua Grant; Maria Fraraccio; Oury Monchi
Journal:  Eur J Neurosci       Date:  2005-12       Impact factor: 3.386

4.  Isometric force-related activity in sensorimotor cortex measured with functional MRI.

Authors:  G W Thickbroom; B A Phillips; I Morris; M L Byrnes; F L Mastaglia
Journal:  Exp Brain Res       Date:  1998-07       Impact factor: 1.972

5.  Eye dominance in the visual cortex using functional MRI at 1.5 T: an alternative method.

Authors:  Grant T Liu; Atsushi Miki; Zachariah Goldsmith; Theo G M van Erp; Ellie Francis; Graham E Quinn; Edward J Modestino; Gabrielle R Bonhomme; John C Haselgrove
Journal:  J AAPOS       Date:  2002-02       Impact factor: 1.220

6.  Dopaminergic modulation of cortical function in patients with Parkinson's disease.

Authors:  Venkata S Mattay; Alessandro Tessitore; Joseph H Callicott; Alessandro Bertolino; Terry E Goldberg; Thomas N Chase; Thomas M Hyde; Daniel R Weinberger
Journal:  Ann Neurol       Date:  2002-02       Impact factor: 10.422

7.  Neural bases of set-shifting deficits in Parkinson's disease.

Authors:  Oury Monchi; Michael Petrides; Julien Doyon; Ronald B Postuma; Keith Worsley; Alain Dagher
Journal:  J Neurosci       Date:  2004-01-21       Impact factor: 6.167

8.  Impaired mesial frontal and putamen activation in Parkinson's disease: a positron emission tomography study.

Authors:  E D Playford; I H Jenkins; R E Passingham; J Nutt; R S Frackowiak; D J Brooks
Journal:  Ann Neurol       Date:  1992-08       Impact factor: 10.422

9.  The metabolic topography of parkinsonism.

Authors:  D Eidelberg; J R Moeller; V Dhawan; P Spetsieris; S Takikawa; T Ishikawa; T Chaly; W Robeson; D Margouleff; S Przedborski
Journal:  J Cereb Blood Flow Metab       Date:  1994-09       Impact factor: 6.200

10.  Reproducibility of fMRI in the clinical setting: implications for trial designs.

Authors:  R Bosnell; C Wegner; Z T Kincses; T Korteweg; F Agosta; O Ciccarelli; N De Stefano; A Gass; J Hirsch; H Johansen-Berg; L Kappos; F Barkhof; L Mancini; F Manfredonia; S Marino; D H Miller; X Montalban; J Palace; M Rocca; C Enzinger; S Ropele; A Rovira; S Smith; A Thompson; J Thornton; T Yousry; B Whitcher; M Filippi; P M Matthews
Journal:  Neuroimage       Date:  2008-05-15       Impact factor: 6.556

View more
  16 in total

1.  The default mode network integrity in patients with Parkinson's disease is levodopa equivalent dose-dependent.

Authors:  L Krajcovicova; M Mikl; R Marecek; Irena Rektorova
Journal:  J Neural Transm (Vienna)       Date:  2011-10-15       Impact factor: 3.575

2.  Levodopa changes brain motor network function during ankle movements in Parkinson's disease.

Authors:  Petra Schwingenschuh; Petra Katschnig; Margit Jehna; Mariella Koegl-Wallner; Stephan Seiler; Karoline Wenzel; Stefan Ropele; Christian Langkammer; Thomas Gattringer; Martin Svehlík; Erwin Ott; Franz Fazekas; Reinhold Schmidt; Christian Enzinger
Journal:  J Neural Transm (Vienna)       Date:  2012-09-19       Impact factor: 3.575

3.  Effects of Parkinson disease and antiparkinson medication on central adaptations to repetitive grasping.

Authors:  Michael J Falvo; John W Rohrbaugh; Thomas Alexander; Gammon M Earhart
Journal:  Life Sci       Date:  2018-03-09       Impact factor: 5.037

Review 4.  Effects of levodopa on regional cerebral metabolism and blood flow.

Authors:  Ji Hyun Ko; Renata P Lerner; David Eidelberg
Journal:  Mov Disord       Date:  2014-10-09       Impact factor: 10.338

5.  Effects of levodopa on vividness of motor imagery in Parkinson disease.

Authors:  Daniel S Peterson; Kristen A Pickett; Gammon M Earhart
Journal:  J Parkinsons Dis       Date:  2012       Impact factor: 5.568

6.  Rhythmic auditory cues shape neural network recruitment in Parkinson's disease during repetitive motor behavior.

Authors:  Kurt Braunlich; Carol A Seger; Kade G Jentink; Isabelle Buard; Benzi M Kluger; Michael H Thaut
Journal:  Eur J Neurosci       Date:  2018-12-03       Impact factor: 3.386

7.  Motor matters: tackling heterogeneity of Parkinson's disease in functional MRI studies.

Authors:  Štefan Holiga; Karsten Mueller; Harald E Möller; Tomáš Sieger; Matthias L Schroeter; Josef Vymazal; Evžen Růžička; Robert Jech
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

8.  The subthalamic microlesion story in Parkinson's disease: electrode insertion-related motor improvement with relative cortico-subcortical hypoactivation in fMRI.

Authors:  Robert Jech; Karsten Mueller; Dušan Urgošík; Tomáš Sieger; Štefan Holiga; Filip Růžička; Petr Dušek; Petra Havránková; Josef Vymazal; Evžen Růžička
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

Review 9.  Magnetic Resonance Techniques Applied to the Diagnosis and Treatment of Parkinson's Disease.

Authors:  Benito de Celis Alonso; Silvia S Hidalgo-Tobón; Manuel Menéndez-González; José Salas-Pacheco; Oscar Arias-Carrión
Journal:  Front Neurol       Date:  2015-07-03       Impact factor: 4.003

10.  Accounting for movement increases sensitivity in detecting brain activity in Parkinson's disease.

Authors:  Štefan Holiga; Harald E Möller; Tomáš Sieger; Matthias L Schroeter; Robert Jech; Karsten Mueller
Journal:  PLoS One       Date:  2012-05-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.